CONVIVO Endomicroscopy
Part of paid clinical trials in Manhasset, New York.
- Sponsor
- Northwell Health
- Study ID
- NCT06087393
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- N/A - N/A
- Healthy Volunteers
- Accepted
Interventions
- CONVIVO — DEVICEAny clinical adverse event (AE), laboratory abnormality, or other medical condition or situation occurs such that continued participation in the study would not be in the best interest of the participant. The participant meets an exclusion criterion (either newly developed or not previously recognized) that precludes further study participation.
Study Details
Visualization of the tissue microstructure during neurosurgery using a non destructive handheld imaging technology producing a real time digital image ("optical biopsy") at cellular resolution is a novel method that holds great promise for optimization and improvement of the surgical treatment of brain pathologies, brain tumors in particular. The goal of this project is to investigate and assess the ease of use of the CONVIVO FDA cleared system in discriminating healthy and abnormal tissues during in vivo use on the brain during neurosurgery in 30 patients with a working diagnosis of intrinsic brain tumors.
Key Dates
- Start date
- Jan 8, 2024
- Status verified
- Jun 2026
- Primary completion
- Oct 12, 2026
- Completion
- Oct 12, 2026
Study Design
- Enrollment
- 30 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- DEVICE_FEASIBILITY
Primary Outcome Measure
Investigate ease of CONVIVO. [ Time Frame: one year ]
Central Contacts
- Betsy Moclair5162537753
Locations (1)
| Facility | City | State | ZIP |
|---|---|---|---|
| Northwell Health | Manhasset | New York | 11030 |
Find similar trials in Manhasset, NY
By condition
By specialty
By research site
Related Studies
- Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOAPHASE2 · Recruiting · Northwell Health · New York, New York
- Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed GlioblastomaPHASE1/PHASE2 · Recruiting · Northwell Health · New York, New York
- Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBMPHASE1/PHASE2 · Recruiting · Northwell Health · New York, New York
- Transgenerational Metabolic-Immune Biomarkers of Neurological and Neurodevelopmental DisordersRecruiting · Southwest Autism Research & Resource Center · Phoenix, Arizona